Overview
Mandibulofacial dysostosis, also known as Treacher Collins syndrome (TCS) or Treacher Collins-Franceschetti syndrome, is a rare genetic disorder that primarily affects the development of bones and other tissues of the face. The condition is present at birth and results from abnormal development of the first and second pharyngeal arches during early embryonic growth. Key clinical features include underdevelopment of the facial bones, particularly the mandible (lower jaw) and zygomatic bones (cheekbones), giving the face a characteristic appearance with a small jaw (micrognathia) and flattened cheeks. Patients frequently have downward-slanting palpebral fissures (eye openings), colobomas (notches) of the lower eyelids, and sparse or absent eyelashes on the lower lids. The external ears are often malformed, small, or absent (microtia or anotia), and conductive hearing loss is common due to abnormalities of the middle ear ossicles and external auditory canals. The severity of mandibulofacial dysostosis varies widely, even among affected members of the same family, ranging from mild cases that may go undiagnosed to severe presentations with significant airway compromise requiring urgent intervention at birth. Cleft palate occurs in approximately one-third of affected individuals. Intelligence is typically normal. The condition primarily affects the craniofacial skeleton, the eyes, and the auditory system. Treatment is multidisciplinary and symptomatic, as there is no cure. Management may include surgical reconstruction of the facial bones, jaw, and ears; hearing aids or bone-anchored hearing devices to address hearing loss; cleft palate repair; and orthodontic treatment. In severe cases, tracheostomy or mandibular distraction osteogenesis may be necessary to secure the airway in the neonatal period. Speech therapy and psychosocial support are also important components of care. Genetic counseling is recommended for affected individuals and their families.
Also known as:
Autosomal dominant
Passed on from just one parent; each child has about a 50% chance of inheriting it
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for Mandibulofacial dysostosis.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Mandibulofacial dysostosis at this time.
New trials open frequently. Follow this disease to get notified.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Mandibulofacial dysostosis.
Community
No community posts yet. Be the first to share your experience with Mandibulofacial dysostosis.
Start the conversation →Latest news about Mandibulofacial dysostosis
No recent news articles for Mandibulofacial dysostosis.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Mandibulofacial dysostosis
What is Mandibulofacial dysostosis?
Mandibulofacial dysostosis, also known as Treacher Collins syndrome (TCS) or Treacher Collins-Franceschetti syndrome, is a rare genetic disorder that primarily affects the development of bones and other tissues of the face. The condition is present at birth and results from abnormal development of the first and second pharyngeal arches during early embryonic growth. Key clinical features include underdevelopment of the facial bones, particularly the mandible (lower jaw) and zygomatic bones (cheekbones), giving the face a characteristic appearance with a small jaw (micrognathia) and flattened c
How is Mandibulofacial dysostosis inherited?
Mandibulofacial dysostosis follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Mandibulofacial dysostosis typically begin?
Typical onset of Mandibulofacial dysostosis is neonatal. Age of onset can vary across affected individuals.
Which specialists treat Mandibulofacial dysostosis?
11 specialists and care centers treating Mandibulofacial dysostosis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.